Although clinical trial data regarding the use of this drug are currently limited, in EML4–ALK xenograft models in mice, Brigitanib exhibits a dose-dependent inhibition of tumor growth, tumor burden, and prolonged survival [97]. This evidence concerns the gene ALK and neoplasm.